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ABSTRACT:  
Myocardial infarction (MI) leads to substantial morbidity and mortality around the world. 
Accurate assessment of myocardial viability is essential to assist therapies and improve 
patient outcomes. 131I-hypericin dicarboxylic acid (131I-HDA) was synthesized and evaluated 
as a potential diagnostic agent for earlier assessment of myocardium viability compared to its 
preceding counterpart 131I-hypericin (131I-Hyp) with strong hydrophobic property, long plasma 
half-life and high uptake in mononuclear phagocyte system (MPS). Herein, HDA was 
synthesized and characterized, and self-aggregation constant Kα was analyzed by 
spectrophotometry. Plasma half-life was determined in healthy rats by γ-counting. 131I-HDA 
and 131I-Hyp were prepared with iodogen as oxidant. In vitro necrosis avidity of 131I-HDA and 
131I-Hyp was evaluated in necrotic cells induced by hyperthermia. Biodistribution was 
determined in rat models of induced necrosis using γ-counting, autoradiography, and 
histopathology. Earlier imaging of necrotic myocardium to assess myocardial viability was 
performed in rat models of reperfused myocardium infarction using single photon emission 
computed tomography/computed tomography (SPECT/CT). As a result, the self-aggregation 
constant Ka of HDA was lower than that of Hyp (105602 vs 194644, p < 0.01). 131I-HDA 
displayed a shorter blood half-life compared with 131I-Hyp (9.21 vs 31.20 h, p < 0.01). The 
necrotic-viable ratio in cells was higher with 131I-HDA relative to that with 131I-Hyp (5.48 vs 
4.63, p < 0.05). 131I-HDA showed a higher necrotic-viable myocardium ratio (7.32 vs 3.20, p 
< 0.01), necrotic myocardium-blood ratio (3.34 vs 1.74, p < 0.05) and necrotic 
myocardium-lung ratio (3.09 vs 0.61, p < 0.01) compared with 131I-Hyp. 131I-HDA achieved 
imaging of necrotic myocardium at 6 h post-injection (p.i.) with SPECT/CT, earlier than 
what131I-Hyp did. Therefore, 131I-HDA may serve as a promising necrosis-avid diagnostic 
agent for earlier imaging of necrotic myocardium compared with 131I-Hyp. This may support 
further development of radiopharmaceuticals (123I and 99mTc) based on HDA for SPECT/CT 
of necrotic myocardium. 
KEYWORDS: SPECT/CT, Radioiodinated hypericin dicarboxylic acid, Myocardial 
infarction, Necrotic myocardium avidity  
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INTRODUCTION 
Myocardial infarction (MI) leads to substantial morbidity and mortality around the world.1, 2 
Timely myocardial revascularization is currently recognized as the most effective therapy for 
MI by decreasing myocardial damage and improving life expectancy.3, 4 However, it is not 
suitable for all MI patients. According to the Occluded Artery Trial (OAT) including over 150 
medical centers worldwide, serious reperfusion injury complications such as myocardial 
rupture, congestive heart failure and a second infarction occurred with a higher rate in patients 
randomized to myocardial revascularization and approximately 10% of patients rapidly died.5, 
6 Severe reperfusion damage mainly occurs in patients with little reversibly viable 
myocardium in the MI area.4 Therefore, assessment of myocardial viability is central to the 
decision-making for revascularization therapies. 
Noninvasive cardiac imaging plays a crucial role in assessment and classification of 
myocardial ischemia and viability among MI patients.7 Currently, most tracers used for 
assessing myocardial viability are through their absorption or distribution in viable 
myocardial region, unavoidably affecting the function of normal myocardium. Positron 
emission tomography (PET) using 18F-FDG (fluorine-18 deoxyglucose) is the gold standard 
for this purpose. Differentiation between normal, stunned, hibernating and necrotic 
myocardium is based on segmental differences in perfusion and metabolism. However, 
18F-FDG is easily influenced by glucose concentration and insulin level leading to false 
negatives and positives.8 Furthermore, the cost of 18F-FDG PET is still too expensive for most 
patients, limiting its wide use in clinical practice. 
Cell death is an important property of diseases including MI. Identifying myocardial 
necrosis by noninvasive imaging modalities can provide diagnostic information to assess the 
extent of myocardial tissue damage.9 Intracellular contents such as histones, fragmented DNA, 
cytoplasmic organoids released by necrotic tissues are potential targets for diagnosis of MI, 
which may avoid disadvantages of imaging viable cells or tissues.10 A number of imaging 
tracers for myocardial necrosis have been evaluated. 99mTc-glucarate could bind negatively 
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charged histones within disintegrated nuclei and shows good sensitivity and specificity for 
early detection of irreversible myocyte injury. Nevertheless, its uptake was limited to a 
clinical window of 9 hours after onset, owing to the relatively rapid disintegration of 
histones.11 Therefore, it is essential to find new necrosis-avid agents for evaluation of 
myocardial viability. 
Hypericin (Hyp, Figure S1a) is a naturally occurring compound isolated from Hypericum 
perforatum (St. John’s Wort). Previous studies demonstrat that 123I-hypericin (123I-Hyp) is a 
promising positive tracer for detection of necrotic myocardium.12, 13 However, the slow blood 
clearance resulting from long plasma half-life caused the delineation of infarct earliest at 9 h 
p.i., which may remarkably delay the rescue of reversibly dysfunctional myocardium in 
patients of myocardial infarction.14 Furthermore, Hyp can easily form supramolecular 
self-aggregates in aqueous medium, which significantly hinders its selective accumulation in 
necrotic tissues and exhibits unwanted biodistribution in mononuclear phagocyte system 
(MPS).15, 16 High lung uptake not only can lead to severe radiation pulmonary disease but also 
seriously influence early imaging quality of necrotic myocardium. 
Introduction of hydrophilic group(s) into molecules is a classical and general strategy for 
improving hydrophilicity and plasma clearance. Moreover, introduction of hydrophilic 
substituents can effectively prevent supramolecular self-aggregates.17 Previous study proved 
that obvious necrosis-avidity was still retained if one methyl group of Hyp was oxidized into 
carboxyl group.18 Therefore, we postulated that replacing two methyl groups with two 
carboxyl groups in Hyp (Figure S1b) could improve hydrophilicity, further shorten plasma 
half-life and reduce unwanted biodistribution in MPS, achieving earlier imaging of necrotic 
myocardium for myocardial viability assessment. 
To validate this hypothesis, we first synthetized 131I-HDA and assessed the elimination rate 
and the extent of self-aggregate by plasma half-life (t1/2) and self-aggregation constants (Kα). 
Necrosis-avidity of 131I-HDA and 131I-Hyp was evaluated by in vitro cell-binding assay and in 
vivo rat models with reperfused hepatic and muscular necrosis. Necrosis-targeting mechanism 
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was preliminarily explored by using excessive Hyp or HDA for blocking experiment. The 
ability to image necrotic myocardium was investigated in rat models of reperfused myocardial 
infarction at 6 h p.i. 
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EXPERIMENTAL SECTION 
Methods and Materials. Emodin, with a purity > 98%, was purchased from JingZhu 
Biological Technology (Nanjing, People’s Republic of China). Hyp (purity > 98.5%) was 
purchased from Purui Technology Co. Ltd (Chengdu, China). Sodium iodide (Na131I, 
radionuclide purity > 99%) was supplied by HTA Co, Ltd, Beijing, China with the specific 
activity 20 mCi/mL. Male adult SD rats (250 ~ 300 g) were purchased from Shanghai Slakey 
Laboratory Animal Co. Ltd. All animal experiments were conducted with the approval of the 
Animal Affairs Committee of Jiangsu Province Academy of Traditional Chinese Medicine. 
All applicable international guidelines on the care and use of animals were followed. 
Drug Preparation. HDA was obtained starting from emodin and purified according to a 
reported four-step procedure (Figure S2).19, 20 
Aggregation. The self-aggregation constant Kα was measured by spectrophotometry in 50% 
dimethylsulfoxide (DMSO) solution according to Monika Pietrzak et al.21 Briefly, compounds 
were dissolved in 50% water-DMSO mixed solvent (v/v) as function of concentrations in a 
range of: 2×10-6 M to 5×10-5 M. Absorption spectra of HDA and Hyp were measured by Cary 
WinUV Cary 60 (Agilent Technologies Inc, California, USA), in a wavelength range of 
200-800 nm at temperature 283 K. The self-aggregation constants Kα in the monomeric form 
and in complexes were estimated numerically. The isodesmic model was applied for 
non-linear regression analysis according to Eq. (1):  
(1): 	,  = 	 	
– 



+ 
 
Where A(λ,C) – absorbance at wavelength λ of the measured samples at total concentration C 
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of Hyp or HDA in solution; εM (λ) and εA(λ)– the extinction coefficients of the monomeric and 
the aggregated Hyp or HDA, respectively; and Kα – self-aggregation constants. The degree of 
aggregated molecules can be written as αagg and can be obtained according to Eq. (2):
17 
 (2):  = 1 −
  
 
 
Where Kα – the self-aggregation constant; c – the total concentration of the compound. Data 
analysis with origin pro 8.0 (originlab, Massachusetts, USA). 
Drug Radiolabelling. The Iodogen-coating method was employed for radioiodination of 
HDA and Hyp with Na131I solution to form 131I-HDA and 131I-Hyp. Briefly, Iodogen (1, 3, 4, 
6-tetrachloro-3 a, 6 adiphenylglycouril; Pierce Biotechnology, ZI Camp Jouven, France) was 
dissolved in an organic solvent and was coated on the walls of the Eppendorf tubes. Hyp or 
HDA was dissolved in DMSO to 0.2 mg/ml solution, respectively. Then the solution was 
added into one Iodogen tube, which was added with Na131I solution (20 mCi/mL) (volume 
ratio, 4:1). The Iodogen tube was incubated at room temperature for 30 min. Radiochemical 
purity was determined by thin-layer chromatography (TLC) using Whatman No.1 filter paper 
and 0.1 N of hydrochloric acid as developing solvent.22 Then the filter paper was cut into two 
sections and each section was measured for radioactivities using a WIZARD2 2470 automated 
gamma counter (PerkinElmer, Waltham, MA). The result was expressed as percentage of 
radioactivity of 131I-HDA or 131I-Hyp relative to all radioiodine activity. The mixture was 
diluted with PEG 400 and propylene glycol (1:1, v/v) for obtaining the injection preparation. 
Labeling Stability Study In Vitro. Radiolabeling reaction mixtures were added in rat 
plasma (1: 9 v/v) to observe the radiolabeling stability in vitro at 37°C. Radiochemical purity 
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of 131I-HDA and 131I-Hyp was determined by thin-layer chromatography as described above.  
LogP Determination. The partition coefficient (P) was expressed as logP. LogP of 
131I-HDA or 131I-Hyp was determined by measuring the distribution of radioactivity in 
1-octanol and PBS.23 500µL of phosphate buffer (0.1 M, pH 7.4) and 500 µL 1-octanol was 
added to an Eppendorf tube, and 1 µCi of 131I-Hyp or 131I-HDA was added to the tube. Then it 
was vortexed for 10min and centrifuged at 12000 rpm for 10 min to ensure the complete 
separation of layers. The counts in 20 µL aliquots of both organic and aqueous layers were 
determined using an automatic γ-counter. The operation was performed in triplicate. The 
partition coefficient (P) was calculated as (cpm in the organic phase-background cpm) / (cpm 
in the aqueous phase-background cpm). 
In Vitro Binding Assay. The human lung cancer A549 cell line was obtained from 
American Type Culture Collection (Manassas, VA) and cultured in RPMI-1640 supplemented 
with 10% fetal bovine serum (FBS) incubated in 5% CO2 humidified atmosphere at 37°C. 
Necrosis was induced after incubation of the cells for 1 h under intense hyperthermia at 
57°C according to Perek et al.24 Briefly, A549 cells were seeded onto one 6-well plate with a 
density of 5×105 cells/well 1 d before the experiment. Then the A549 cells were induced 
necrosis after incubation for 1 h under intense hyperthermia at 57°C. Nontreated cells were 
used as a control. The two types of cells in duplicate were incubated with 131I-HDA or 
131I-Hyp (1 µCi/ml) for 15 min and washed twice with PBS. The culture supernatant and cells 
were collected by centrifuging at 12000 rpm for 15 min respectively. The radioactivity was 
counted using an automated gamma counter. The data were expressed as the percentage 
uptake per 108 cells. Experiments were performed in triplicate. 
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Animal Models of Necrosis. Rat models of reperfused hepatic infarction and muscular 
necrosis were conducted as previously described.25 All rats were given drinking water 
containing 0.12% potassium iodide (0.1 g KI was added to 100 ml drinking water) from 3 d 
before experiment till the end of experiment to minimise thyroid uptake of free 131I. The rats 
were anaesthetized with intraperitoneal injection of pentobarbital (Nembutal Veterinary; 
Sanofi Sante Animale, Paris, France) at a dose of 40 mg/kg. Under laparotomy, hilum of the 
right liver lobe was clamped for 3 h, and then released to resume hepatic inflow for perfusion 
of the infarcted hepatic lobe. After reperfusion, the abdominal cavity was closed with 
two-layer sutures. Each model rat was intramuscularly injected with 0.2 mL absolute alcohol 
in the left leg to establish chemically induced muscular necrosis. All model rats were allowed 
to recover for at least 8 h after the procedure.  
Rat models of reperfused myocardial infarction were conducted as previously described.26 
Briefly, each rat, whose thyroid gland was blocked as described above, was anaesthetized 
with intraperitoneal injection of pentobarbital, intubated and artificially ventilated with air 
using a rodent ventilator. Open chest surgery was performed. The pericardium was opened to 
expose the left circumflex coronary artery, which was ligated with a single detachable knot. 
The sham operation was identical, but the left circumflex coronary artery was not ligated. The 
chest was closed after evacuation of the pneumothorax. One hour after occlusion, the suture 
end was pulled to achieve coronary reperfusion. 
Pharmacokinetics. The thyroid glands of twelve healthy rats were blocked with potassium 
iodide as described above from 3 d before experiment till the end of experiment. The rats 
were randomly assigned into two groups and were intravenously injected with 14.8 MBq/kg 
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(0.2 mg/kg) of 131I-HDA or 131I-Hyp solution under anesthesia. Then, 10 µL of blood were 
taken through tail vein at 5 min, 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 12 h and 24 h p.i., 
respectively. Blood samples were measured for radioactive counts using an automatic 
γ-counter. Backups of 131I-HDA and 131I-Hyp solutions were used as decay correction 
standards. Measured activity was expressed as radioactivity of each liter of blood (MBq/L). 
The pharmacokinetic parameters were calculated by the statistical moment method of the 
noncompartment model using Drug and Statistics for windows 2.0 software (SAS Inc., Cary, 
NC). 
Biodistribution Studies and Blocking Experiment. Forty rats of reperfused hepatic 
infarction and muscular necrosis model were randomly divided into eight groups (n = 5) with 
their thyroid glands blocked as described above. Three groups were injected (i.v.) with 14.8 
(0.2 mg/kg) MBq/kg of 131I-HDA solution via the tail vein, and the other 3 groups were 
injected (i.v.) with 14.8 MBq/kg (0.2 mg/kg) of 131I-Hyp solution. Then rats were sacrificed 
by groups at 6, 12, and 24 h. The last two groups were performed by coinjection of 14.8 
MBq/kg (0.2mg/kg) of 131I-HDA with 10 mg/kg of cold Hyp and HDA respectively, and then 
sacrificed at 6 h p.i.27 At each time point, the tissues of interest were sampled, weighed and 
radioactivity was measured for radioactive counts as has been stated above and corrections 
were made for background radiation and physical decay during counting. The results were 
presented as percentage of the injected dose per gram of tissues (%ID/g). 
Tissues of necrotic liver, normal liver and necrotic muscle were cut into 30 µm frozen 
sections with a cryotome (Shandon; Thermo Fisher Scientific, Waltham, MA, USA), and 
exposed to a high performance storage phosphor screen (Super resolution screen; 
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Canberra-Packard, Ontario, Canada) for 4~24 h. Images of the screen were read using 
Optiquant software (Cyclone; Canberra-Packard, Ontario, Canada), and the radioactivity was 
expressed in digital light units (DLU)/mm2. The tissue slides were then stained with 
hematoxylin and eosin (H&E), digitally photographed, and compared with autoradiographs. 
Wholebody Autoradiography Imaging. Rats with reperfused hepatic infarction were 
assessed by whole-body autoradiography after being injected (i.v.) with 131I-HDA and 
131I-Hyp respectively under anesthesia. Rats were subjected to whole-body cryosectioning, 
exposure, and imaging at 6 h p.i. as described previously.28 Briefly, carcasses were embedded 
in sodium carboxymethylcellulose and stored at − 20°C until sectioning. Coronal sections of 
120 µm thickness were obtained using a cryotome (CM 3600 PLC, Leica Cryosystems GmbH, 
Nussloch, Germany). The sections were lyophilized and mounted onto a plastic plate with all 
major interesting tissues and organs included for autoradiography exposure with a high 
performance storage phosphor screen during 10 ~ 30 min. 
Rats with myocardial infarction (n = 10) with thyroid glands blocked were randomly 
assigned into two groups (n = 5) with 131I-HDA and 131I-Hyp i.v. injected at 14.8 MBq/kg (0.2 
mg/kg) respectively under anesthesia. SPECT/CT imaging was conducted at 6 h after 
injection of 131I-HDA or 131I-Hyp. The SPECT/CT system (Precedence 6; Philips) consisted of 
a variable-angle dual-detector with low-energy high-resolution collimators and a multislice 
spiral CT component optimized for rapid rotation. The SPECT acquisition (128 × 128 matrix, 
30 frames) was performed using 6° angular steps in a 25-s time frame. For CT (120 kV, 240 mA, 
0.75s/r), 1-mm slices were obtained. After reconstruction, SPECT images were corrected for 
attenuation and scatter. Both SPECT and CT 1-mm slices were generated using an Astonish bone 
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application package (Philips) and were transferred to a picture archiving and communication 
systems after generation of DICOM files. SPECT/CT images were fused using the Syntegra 
software (Philips).  
The rats were sacrificed immediately after SPECT/CT imaging. Organs of interest were 
sampled, weighed separately, and counted for radioactivity as described above. The heart was 
rinsed with saline to remove blood pool activity, and cut into 3-mm-thick short-axis blocks. 
Subsequently, the myocardium blocks were stained in a 2% buffered triphenyltetrazolium 
chloride (TTC) solution for 15 min at 37°C and digitally photographed for later match of 
imaging–histochemistry. The TTC stained blocks were cut at − 20°C into 50-µm sections. 
Relative tracer concentration in the necrotic and viable myocardium slices was estimated by 
regions of interest analysis from all autoradiography as described above. Guided by TTC 
staining,13 the necrotic portions of the remaining unsliced parts of the myocardium were 
separated from the normal myocardium, weighed and counted for radioactivity as described 
above. 
Statistical Analysis. Quantitative data were expressed as mean ± standard deviation (SD). 
A one-way ANOVA was used to test differences among groups, and p < 0.05 was considered 
for a statistically significant difference. 
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RESULTS 
Synthesis and Structural Identification of HDA. HDA was obtained starting from 
emodin and purified in an overall yield of 20%. The molecular formula was determined as 
C30H12O12 from the measured ES-TOF-MS ion peak [M-H]
-1 at m/z 563.1 (calculated for 
C30H12O12, [M-H]
- 564.0). Thus, the structure of hypericin dicarboxylic acid (HDA) was 
identified by comparison of the NMR data with the reference.20 
Aggregation. The self-aggregation constants Ka of HDA and Hyp were 105602 ± 11743 
and 194644 ± 15557 (p < 0.01), respectively. The concentration-dependent transitions from 
monomeric to aggregated HDA and Hyp (symbols) and the calculated regression lines 
according to the isodesmic model were shown in Figure S3. The αagg regression lines showed 
that the self-aggregation extent of HDA was obviously lower than Hyp in the same 
concentration. 
Radiolabelling and In Vitro Stability Assay. The TLC data showed the RCP of 131I-HDA 
and 131I-Hyp was in average of 97.8% ± 2.6% and 98.5% ± 2.8%, respectively, and stable up 
to 24 h. Similarly, the radiochemical purity of 131I-HDA and 131I-Hyp formulations in plasma 
was 96.1% ± 2.5% and 96.7 ± 2.9% up to 24 h, respectively. 
LogP Determination. The partition coefficients (logP) of 131I-HDA and 131I-Hyp was 
measured to be 0.65 ± 0.03 (n = 3) and 2.96 ± 0.10 (n = 3) (p < 0.01), suggesting that 
131I-HDA was 200-fold of 131I-Hyp in hydrophilism. 
In Vitro Binding Assay. The performance of 131I-HDA and 131I-Hyp to target necrotic cells 
is summarized in Table. 1. Compared to non-treated cells, there was a 5.48 ± 0.17 and 4.63 ± 
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0.15 folds (p < 0.05) increase in the uptake of 131I-HDA and 131I-Hyp respectivelyin the 
induced necrotic cells. The viable cells uptake was significantly lower for 131I-HDA than for 
131I-Hyp (p < 0.05), while the uptake of necrotic cells for 131I-HDA and 131I-Hyp showed no 
significant difference (p > 0.05). 
Pharmacokinetics. The major pharmacokinetics parameters are summarized in Table 2. 
The elimination half-life (t1/2z) showed that the blood clearance of 
131I-HDA (t1/2z = 9.21 ± 
1.58 h) was faster than 131I-Hyp (t1/2z = 31.20 ± 3.39) (p < 0.001). The AUC(0–t) and AUC(0–∞) 
of 131I-Hyp were also larger than that of 131I-HDA (p < 0.05), which were, respectively, 
1112.28 ± 108.84 MBq/L*h, 1172.32 ± 97.88 MBq/L*h of 131I-Hyp and 519.60 ± 56.28 
MBq/L*h, 588.14 ± 40.72 MBq/L*h of 131I-HDA. 
Biodistribution Studies. The biodistribution data are summarized in Table S1 and Figure 1 
with the results expressed as mean %ID/g ± SD. The %ID/g value of blood for 131I-HDA was 
approximately a half of 131I-Hyp at each time point (p < 0.05). The lung uptake was 
significantly lower for 131I-HDA than for 131I-Hyp at three time points (p < 0.001). The 
normal myocardium uptake of 131I-HDA was approximately one third of 131I-Hyp at each time 
point (p < 0.05). However, uptake of 131I-HDA was slightly higher than that of 131I-Hyp in the 
kidney and normal liver. Because of the faster clearance, uptake of 131I-HDA was lower than 
of 131I-Hyp in most organs. The necrotic-normal liver ratios of 131I-HDA were 3.32, 8.40 and 
13.03, and the necrotic-normal muscle ratios were 7.11, 10.28, and 14.20, respectively at 6, 
12 and 24 h. For 131I-Hyp, the necrotic-normal liver ratio was 4.14, 10.65 and 16.72, and the 
necrotic-normal muscle ratios was 3.91, 6.13, and 11.40, respectively at 6, 12 and 24 h. The 
results showed that the necrotic-normal liver ratio of 131I-HDA was lower than that of 
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131I-Hyp at each time point. However, the necrotic-normal muscle ratio of 131I-HDA was 
higher than that of 131I-Hyp. 
Autoradiography and Immunohistochemical Staining. Figure 2 represents 
autoradiography and immunohistopathology outcomes. As seen on H&E stained slices, the 
dark purple regions were viable muscle and liver and the light pink parts were eosinophilic 
necrotic muscle and liver. Higher tracer uptake appeared in the necrotic liver and muscle 
compared to the viable counterparts. 131I-HDA and 131I-Hyp mainly retained in the necrotic 
regions, supporting the γ-counting results. Whole body autoradiography images at 6 h p.i. are 
shown in Figure 3. The uptake in lung and heart was apparently lower with 131I-HDA than 
with 131I-Hyp. However, 131I-HDA displayed slightly higher than that of 131I-Hyp in normal 
liver. There was no significant difference between the uptake of necrotic liver for 131I-HDA 
and 131I-Hyp.  
Blocking Experiment. As shown in Figure 4a, excessive cold Hyp significantly reduced 
the uptake of 131I-HDA in necrotic liver (0.77 ± 0.05 %ID/g) and muscle (0.15 ± 0.02 %ID/g) 
compared to the no-block group (3.41 ± 0.14 and 0.50 ± 0.04 %ID/g), respectively (p < 
0.001), indicating that about 77% and 70% of the radioactivity were blocked by Hyp. 
Meanwhile, excessive cold HDA also successfully reduced the uptake of 131I-HDA in necrotic 
liver (0.68 ± 0.04 %ID/g) and muscle (0.12 ± 0.02 %ID/g) compared with the no-block group, 
about 80% and 77% of the radioactivity were blocked by HDA. The results were proved by 
autoradiography and H&E staining in Figure 4b. Figure 4b showed that high 131I-HDA uptake 
appeared only in the necrotic parts (pink coloured on H&E images staining). Whereas low 
131I-HDA uptake was found in the living parts (purple coloured after H&E staining). The 
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imaging of autoradiography and histopathology consisted with the results from biodistribution. 
It suggests that 131I-HDA, cold HDA and Hyp should have the same specific targets of 
necrotic tissues.  
Reperfused Myocardial Infarction Imaged by SPECT/CT. The representative cardiac 
SPECT/CT images of 131I-HDA and 131I-Hyp in sham-operated controls and myocardial 
infarction models are described in Figure 5. In the sham-operated control rats, 131I-Hyp had 
strong background radiation, but not in case of 131I-HDA. 
Myocardial TTC Staining and Autoradiography. The radioactivity ratio of the main 
tissues, TTC and autoradiography of myorcardium are displayed in Figure 6. Radioactivity in 
the necrotic myocardium was 1.17 ± 0.16 %ID/g, which was 7.32 times that found in the 
viable myocardium (0.16 ± 0.02 %ID/g) with 131I-HDA. The value with 131I-Hyp in necrotic 
myocardium (1.34 ± 0.12 %ID/g) was about 3.20 times that in viable myocardium (0.42 ± 
0.03%ID/g) as supported by autoradiogram (Figure 6a). For 131I-HDA, the necrotic 
myocardium-blood and necrotic myocardium-lung ratios were 3.34 ± 0.66 and 3.09 ± 0.57 at 
6 h p.i., respectively. And the ratios for 131I-Hyp were 1.74 ± 0.12 and 0.61 ± 0.03, 
respectively at the same time points. However, the normal liver uptake of 131I-HDA was 
higher than that of 131I-Hyp. The infarct-normal myocardium ratios obtained by 
autoradiography were 12 and 8 at the infarct core for 131I-HDA and 131I-Hyp, respectively 
(Figure 6b).The ratio by autoradiography was higher than that by gamma counting due to the 
impurity of normal tissue sampled for γ-counting although sampling necrotic portions was 
guided by TTC staining (Figure 6b). 
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DISCUSSION 
In order to achieve in vivo earlier imaging of necrotic myocardium, we herein synthesized 
HDA by Hyp modification with two hydrophilic carboxylic acids. 131I-HDA was prepared, 
characterized, and evaluated for necrosis avidity. Our findings revealed that 131I-HDA 
presented higher hydrophilicity, more rapid clearance from circulation and lower blood pool 
effect compared with131I-Hyp. Furthermore, 131I-HDA displayed less lung uptake and higher 
necrotic-viable myocardium ratio. Therefore, 131I-HDA achieved earlier imaging of necrotic 
myocardium than 131I-Hyp after administration. 
In the present study, viable cells showed a lower 131I-HDA uptake compared with 131I-Hyp 
(p < 0.05), probably because negatively charged 131I-HDA was more difficult to negotiate 
across the negatively charged cell membrane due to charge repulsion. Although there was no 
significant difference between 131I-HDA and 131I-Hyp in radioactivity concentration of 
necrosis myocardium (p > 0.05), 131I-HDA uptake was significantly less in normal 
myocardium than 131I-Hyp (p < 0.001), consequently, 131I-HDA showed a higher 
necrotic-viable myocardium tissue ratio than 131I-Hyp. Introduction of hydrophilic carboxyl 
groups might reduce the binding of 131I-HDA to plasma protein, resulting in enhanced plasma 
clearance and weakened initial blood pool effect. Carboxyl groups maybe add specific effects 
arising from hydrogen bonding between solvent molecules and the hydrophilic groups, 
lowering strong π–π stacking interactions. Therefore, relatively small amount of 131I-HDA 
was intercepted by pulmonary capillary, which may reduce radiation-induced lung injury and 
abate the interference on imaging of necrotic myocardium. Unsatisfactorily, the normal liver 
uptake of 131I-HDA was slightly higher than 131I-Hyp. The reason may be self-aggregation 
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extent of 131I-HDA decreased relative to 131I-Hyp, but was not completely eliminated. The 
tracer aggregates in plasma are likely phagocytosed by macrophages and Kuepfer cells in the liver, 
leading to the high uptake in liver. Therefore, it is necessary to further reduce the 
self-aggregation of 131I-HDA by introduction more hydrophilic groups such as sulfo group 
and phosphate group to improve the imaging quality of myocardial infarction. 
In the blocking study, necrotic tissues’ uptake of 131I-HDA was significantly decreased by 
the coinjection of excessive Hyp and HDA. The blocking study indicated 131I-HDA, HDA and 
Hyp probably have the same specific targets. However, it is necessary to identify the specific 
binding moiety in further research. Present study demonstrates that the structural modification 
method is applicable to Hyp. 
A number of imaging tracers for myocardial necrosis have been evaluated. 111In-antimyosin 
has a selective avidity for the intracellular heavy chain of cardiac myosin exposed when the 
integrity of the sarcolemma is lost as a result of cell damage. 111In-antimyosin has been 
employed for the detection of myocardial necrosis associated with myocardial infarction, 
myocarditis29 and cardiac allograft rejection30 However, potential macromolecule 
immunogenicity and limitation of approved indications have resulted in cessation of 
commercial production. 131I-HDA, a small molecule necrosis avid tracer agent, may be more 
advantageous than 111In-antimyosin due to less immunogenicity. 99mTc-glucarate can be used 
for visual diagnosis of necrotic myocardium and has favorable imaging characteristics, but its 
target histone bodies are quickly washed out of the tissue after onset (< 9h), which limits its 
clinical use.31 However, it was feasible to permit necrotic myocardium imaging for 131I-HDA 
after 30 hours onset, which suggests that the necrotic target of 131I-HDA was more stable than 
Page 18 of 36
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19 
 
histone bodies. Therefore, radioiodinated HDA may have a broader prospect of clinical 
applications than 99mTc-glucarate. However, this has to be evaluated in follow-up studies. In 
addition, we have to admit that high liver uptake of 131I-HDA may interfere the imaging of 
necrotic myocardium. 
Revascularization time windows for mechanical thrombectomy are generally restricted to 8 
h.32 Since stunned or hibernating myocardium can be saved from infarction if it is reperfused 
promptly by unblocking the occluded vessel, thereby increasing blood flow to the reversible 
dysfunctional myocardium. This study demonstrated that 131I-HDA could guide the use of 
interventions for myocardial salvage through early imaging of necrotic myocardium to 
assess myocardial viability. However, the time of imaging is still long for patients with 
myocardial infarction. Therefore, further optimization is necessary to realize the earlier 
imaging of necrotic myocardium, e.g. acceleration of plasma clearance and uptake reduction 
by living cells. 
Cell death molecular imaging has a surfeit of challenges that it has yet to overcome.2, 9, 10 
One of the most important problems is that none of cell death imaging contrast agents have 
been applied in clinical due to the unsatisfied safety or effectiveness. Other challenges include 
choices of a relevant molecular target, the accurate detection in the temporal and spatial 
occurrence of cell death, as well as the minimized non-targeted biodistribution and 
maximized image contrast. The cost of these novel tests is also a problem which patients have 
attention at all times. 
In this study, Iodine-131 (physical half-life: 8.04 days) was used for imaging of necrotic 
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myocardium due to longer physical half life of Iodine-131 and intended lengthy observation 
period. Iodine-123 (physical half-life: 13.02 hours) or other gamma tracers with shorter 
physical half life may be better for the diagnostic purpose. Furthermore, necrotic myocardium 
was not observed clearly in the cardiac SPECT/CT images. However, ex vivo 
autoradiography in combination with immunohistochemical staining techniques convincingly 
confirmed the accumulation of 131I-HDA or 131I-Hyp in necrotic myocardium. Further studies 
are necessary to demonstrate the earliest time point after 131I-HDA administration at which 
diagnostically useful images can be obtained. 
CONCLUSION 
This study demonstrated that the introduction of negatively charged hydrophilic carboxyl 
groups on Hyp could reduce the extent of self-aggregation, lessen the absorption of 
radioactivity by living cells and accelerate radioactivity clearance from blood, simultaneously 
possess favorable avidity for necrotic tissues. Therefore, 131I-HDA may serve as a promising 
necrosis-avid diagnostic agent. Moreover, the results suggest that it is an effective way to 
introduce negatively charged hydrophilic groups on naphthodianthrones to accelerate imaging 
time and improve the quality of nuclear imaging for necrotic tissues. 
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ABBREVIATIONS 
MI, Myocardial infarction; HDA, hypericin dicarboxylic acid; SPECT/CT, single photon 
emission computed tomography/computed tomography; PET, positron emission tomography 
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Table 1. Accumulation of 131I-Hyp and 131I-HDA in A549 cells 
 131I-HDA 131I-Hyp 
Control  0.073 ± 0.007 0.094 ± 0.010 
Necrosis  0.402 ± 0.035 0.437 ± 0.046 
Necrosis/ Control 5.51 4.64 
Each value is the Mean ± SD % uptake/108 cells. 
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Table 2. Major pharmacokinetics parameters derived by non-compartmental modeling after 
i.v. administration of 131I-HDA and 131I-Hyp at 14.8 MBq/kg (0.2 mg/kg) in healthy rats 
within 24 h p.i. (n = 6) 
 
 
 
 
 
 
AUC(0– t) and AUC(0–1): area under the curve; t1/2z: elimination half-life; Tmax: peak time; CLz: 
clearance; Cmax: peak concentration. The values are expressed as mean ± SD 
  
Parameter Unit Value for HDA Value for Hyp 
AUC(0-t) MBq/L*h 519.60 ± 56.28 1112.28 ± 108.84 
AUC(0-∞) MBq/L*h 588.14 ± 40.72 1172.32 ± 97.88  
t1/2z h 9.21 ± 1.58 31.20 ± 3.39 
Tmax h 0.01 ± 0.00 0.17 ± 0.01 
CLz L/h/kg 0.02 ± 0.00 0.01 ± 0.00 
Cmax MBq/L 136.51 ± 13.76 194.45 ± 13.64 
Page 29 of 36
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30 
 
 
Figure 1. Biodistribution analysis of 131I-HDA and 131I-Hyp, as determined by gamma 
counting in rat models of reperfused hepatic infarction and muscular necrosis at 6 h, 12 h, and 
24 h (n = 5). The injection dose of 131I-HDA or 131I-Hyp is 14.8 MBq/kg (0.2 mg/kg). Data are 
expressed as average percentage injected dose per gram of tissue plus or minus standard 
deviation (%ID/g ± SD). Small Intestine (S Intestine) Normal (Nor) Necrotic (Nec). 
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Figure 2. Images of autoradiography (Aut) and H&E staining from 30 µm frozen sections of 
131I-HDA and 131I-Hyp (14.8 MBq/kg, 0.2 mg/kg) at 6, 12 and 24 h p.i.. Partially necrotic (nec) 
muscle, necrotic (Nec) liver, and normal (Nor) liver. Necrosis (N), viable (V)  
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Figure 3. Whole body autoradiographic imaging of RHI model rats to illustrate the 
biodistribution of 131I-HDA and 131I-Hyp (14.8 MBq/kg, 0.2 mg/kg) at 24 h p.i. Both a digital 
photograph (dig) (a and c) and a corresponding autoradiograph (aut) (b and d) image are 
included. The following tissues are labeled in each image: heart (h), lung (lu), liver (l), 
necrotic liver (nl), and feces (f) 
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Figure 4. 
131I-HDA (14.8 MBq/kg, 0.2 mg/kg) was blocked by excessive Hyp or HDA (10 
mg/kg) in RHI&MN model rats. a Uptake of 131I-HDA in no blocked and 10 mg/kg Hyp or 
HDA blocked necrotic liver and necrotic muscle. The results are presented as %ID/g 6 h after 
co-injection (p < 0.001). b Autoradiograms (upper panels), corresponding H&E images 
(middle panels) and micrograph (lower panels) of partially necrotic (nec) muscle and necrotic 
(nec) liver sections. No blocked (NB) partially necrotic muscle (A1-A3); 10 mg/kg Hyp 
(B-Hyp) (B1-B3) or HDA (B-HDA) (C1-C3) blocked partially necrotic muscle; No blocked 
necrotic liver (D1-D3); 10 mg/kg Hyp (E1-E3) or HDA (F1-F3) blocked necrotic liver. 
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Figure 5. SPECT/CT images (coronal and transversal sections) obtained at 6 h post injection 
of 131I-HDA (A, B) Contrand 131I-Hyp (C, D) in rats with reperfused myocardium infarction  
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Figure 6. a the %ID/g ratio of necrotic myocardium/normal myocardium (Nec M/Nor M), 
necrotic myocardium/blood (Nec M/B), necrotic myocardium/lung (Nec M/Lu), necrotic 
myocardium/liver (Nec M/Li) for 131I-HDA and 131I-Hyp. b Digital photographs of 3 mm 
myocardial slices after TTC staining. Infarcted areas are clearly visible as TTC-negative (pale) 
while viable myocardial areas are stained brick red (TTC-positive). Corresponding 
autoradiograms of serial 30 mm sections with regions of high 131I-HDA and 131I-Hyp uptake 
(red), perfectly matching the TTC-negative areas, and low uptake in viable myocardial 
regions. TTC-stained microphotograph proves the presence of myocardium infarction (MI). 
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